Endothelin-a receptor antagonism after renal angioplasty enhances renal recovery in renovascular disease

• Published in: Journal of the American Society of Nephrology Vol. 26; no. 5; pp. 1071 - 1080
• Main Authors: Chade, Alejandro R, Tullos, Nathan, Stewart, Nicholas J, Surles, Bret
• Format: Journal Article
• Language: English
• Published: United States American Society of Nephrology 01.05.2015
• Subjects: Angioplasty; Animals; Basic Research; Endothelin A Receptor Antagonists - therapeutic use; Endothelin B Receptor Antagonists - therapeutic use; Hypertension, Renovascular - drug therapy; Hypertension, Renovascular - surgery; Kidney Function Tests; Random Allocation; Renal Artery Obstruction - drug therapy; Renal Artery Obstruction - surgery; Swine; renal artery stenosis; endothelin-1; imaging; microcirculation; angioplasty
• ISSN: 1046-6673; 1533-3450
• DOI: 10.1681/asn.2014040323

Percutaneous transluminal renal angioplasty/stenting (PTRAS) is frequently used to treat renal artery stenosis and renovascular disease (RVD); however, renal function is restored in less than one half of the cases. This study was designed to test a novel intervention that could refine PTRAS and enhance renal recovery in RVD. Renal function was quantified in pigs after 6 weeks of chronic RVD (induced by unilateral renal artery stenosis), established renal damage, and hypertension. Pigs with RVD then underwent PTRAS and were randomized into three groups: placebo (RVD+PTRAS), chronic endothelin-A receptor (ET-A) blockade (RVD+PTRAS+ET-A), and chronic dual ET-A/B blockade (RVD+PTRAS+ET-A/B) for 4 weeks. Renal function was again evaluated after treatments, and then, ex vivo studies were performed on the stented kidney. PTRAS resolved renal stenosis, attenuated hypertension, and improved renal function but did not resolve renal microvascular rarefaction, remodeling, or renal fibrosis. ET-A blocker therapy after PTRAS significantly improved hypertension, microvascular rarefaction, and renal injury and led to greater recovery of renal function. Conversely, combined ET-A/B blockade therapy blunted the therapeutic effects of PTRAS alone or PTRAS followed by ET-A blockade. These data suggest that ET-A receptor blockade therapy could serve as a coadjuvant intervention to enhance the outcomes of PTRAS in RVD. These results also suggest that ET-B receptors are important for renal function in RVD and may contribute to recovery after PTRAS. Using clinically available compounds and techniques, our results could contribute to both refinement and design of new therapeutic strategies in chronic RVD.